Price History

Hover for the daily close. The dotted line marks the period open.

Compare VYGR with… →

VYGR Key Statistics

As of Sep 4, 2026

Trading

Open: $3.34
Previous Close: $3.38
Day's Range: 3.33–3.52
52-Week Range: 2.94–5.55
Volume: 406.70K
Beta: 1.32

Valuation

Market Cap: $216.28M
P/E Ratio: unprofitable
P/S ratio: 6.28
EPS (ttm): −1.81

Financials (FY)

Revenue (FY): $40.37M−49.53%
Net Income (FY): −$119.72M
Profit margin: 0.00%
Shares Outstanding: 61.62M
1-Year Return: −9.54%

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 592.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VYGR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−62.10%+125.09%−10.69%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−10.69%
2025	−30.69%
2024	−32.82%
2023	+38.36%
2022	+125.09%
2021	−62.10%
2020	−48.75%
2019	+48.40%
2018	−43.37%
2017	+30.30%
2016 (partial year)	−21.65%

As of September 4, 2026.

VYGR Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$40.37M	−$119.72M	−296.5%
2024	$80.00M	−$65.00M	−81.3%
2023	$250.01M	$132.33M	52.9%
2022	$40.91M	−$46.41M	−113.4%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$40.37M	—	−$131.84M	−$119.72M	−296.5%
2024	$80.00M	—	−$83.29M	−$65.00M	−81.3%
2023	$250.01M	—	$122.01M	$132.33M	52.9%
2022	$40.91M	—	−$50.84M	−$46.41M	−113.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VYGR Valuation vs Biotechnology Median

Median of 656 stocks

Metric	VYGR	Biotechnology median	vs median
P/S ratio	6.28	15.26	59% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Voyager Therapeutics, Inc. (VYGR) is capitalised at $216.28M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 141 employees.

The 52-week range on file runs from $2.94 to $5.55. VYGR last closed at $3.51 on September 4, 2026. That is +$0.13 (+3.85%) against the previous close. The latest close sits 19.39% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $40.37M. Against the prior fiscal year total of $80.00M, that is a change of −49.53%. The same year closed with a net loss of $119.72M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.81.

Across the 4 fiscal years on file, revenue moves from $40.91M in 2022 to $40.37M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 6.28. On price-to-sales that is 58.88% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −9.54%. Measured over 10 years, that is −11.34% a year compounded. The reported beta is 1.32. Daily returns over the trailing 10 years annualize to a volatility of 75.59%.

Growth & Income

No dividend is on file for VYGR.

Across the complete calendar years on file, 2022 returned +125.09% and 2021 returned −62.10%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −10.69% year to date.

Peer Comparison

Voyager Therapeutics, Inc. (VYGR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Voyager Therapeutics, Inc.	VYGR	$216.28M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Voyager Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Visit website →

Voyager Therapeutics, Inc. (VYGR) Stock Analysis